Disclosed are compounds of formulae:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are usefl for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

Disclosed are compounds of formulae:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.13, R.sub.14, R.sub.15, R.sub.16, R.sub.17, n, and m are defined herein. These compounds are usefl for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

In one aspect, the invention relates to compounds having the formula I: ##STR00001##
where R.sup.1-R.sup.6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1-R.sup.6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

In one aspect, the invention relates to compounds having the formula: ##STR00001##
where R.sup.1-R.sup.6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

The present invention is directed to novel pyrrolidine carboxylic acid derivatives, pharmaceutical compositions, and their use in treating and/or preventing metabolic diseases as agonists of g-protein coupled receptor 43.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.

Provided is an -aminoalkylphenone compound that has good stability and low sublimability, efficiently generates radicals when irradiated with a bright line at 365 nm (I line) or the like, and is useful as a polymerization initiator to be used in a radically polymerizable composition. The -aminoalkylphenone compound is represented by Formula (I) mentioned below.

##STR00001##

In Formula (I) mentioned above, it is preferable that R.sup.11 is a nitro group, an alkoxy group having 1 to 12 carbon atoms, or an alkoxycarbonyl group having 1 to 12 carbon atoms. The -aminoalkylphenone compound can be preferably used in a polymerization initiator.

Provided is an -aminoalkylphenone compound that has good stability and low sublimability, efficiently generates radicals when irradiated with a bright line at 365 nm (I line) or the like, and is useful as a polymerization initiator to be used in a radically polymerizable composition. The -aminoalkylphenone compound is represented by Formula (I) mentioned below.

##STR00001##

In Formula (I) mentioned above, it is preferable that R.sup.11 is a nitro group, an alkoxy group having 1 to 12 carbon atoms, or an alkoxycarbonyl group having 1 to 12 carbon atoms. The -aminoalkylphenone compound can be preferably used in a polymerization initiator.

In one aspect, the invention relates to compounds having the formula I:

##STR00001##

where R.sup.1-R.sup.6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.